CANCER TYPE
PROCEDURE
AGE TO BEGIN
RISK FOR GENERAL POPULATION *
Medullary Thyroid
Lifetime risk
Up to 100%
<0.1%
Pheochromocytoma
To age 80
Up to 50%
<0.1%
Other MEN2A, FMTC and MEN2B-associated tumors and cancers
To age 80
Depends on gene mutation
NA
RET
Associated Syndrome
Multiple Endocrine Neoplasia Type 2A (MEN2A), Familial Medullary Thyroid Cancer (FMTC), and Multiple Endocrine Neoplasia Type 2B (MEN2B)
Core Cancer Risk(s)
Medullary Thyroid Cancer
Inheritance
Autosomal Dominant
Prevalence
Unknown
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Medullary Thyroid
Thyroidectomy
ndividualized, based on risk associated with specific RET mutations (infancy, early childhood, or after screening detects signs of thyroid cancer)
NA
Screening with biochemical testing, physical exam and thyroid ultrasound for patients with lower risk mutations
Age 6 months to 5 years
Every 6 months to annually
Pheochromocytoma
Biochemical screening of blood and urine
Individualized, based on risk associated with specific RET mutations (age 8 to 16)
Annually
Abdominal/pelvic MRI (preferred) or CT
If biochemical screening is abnormal
Individualized
Other MEN2A, FMTC and MEN2B-associated tumors and cancers
Biochemical screening for hypercalcemia for individuals with RET mutations associated with hyperparathyroidism
Age 11 to 16
Annually
Additional clinical monitoring for clinical features of MEN2A and MEN2B based on mutation identified
Individualized
Individualized